The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling.

Sebastian KrugLaura MattheisMonika HaemmerleJonas RosendahlJoerg KleeffPatrick Michl

Published in: Cancer reports (Hoboken, N.J.) (2021)

Patients with Wnt/ß-catenin activation may benefit from combination therapy with atezolizumab and bevacizumab regardless of potential predictive markers for immune checkpoint inhibition.

Keyphrases

combination therapy
metastatic colorectal cancer
cell proliferation
stem cells
epithelial mesenchymal transition
risk assessment
signaling pathway